Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026)
Vireo Growth's (VREOF) quarterly Depreciation & Amortization (CF) came in at $4.0 million in Q1 2026, up 566.67% year-on-year from $600000.0 in Q1 2025, and down 66.43% quarter-over-quarter from $11.9 million in Q4 2025.
Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $4.0 million for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $4.0 million, up 566.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (up 679.43% YoY), and the FY2025 annual result was $16.1 million, up 535.04% from the prior year.
- Depreciation & Amortization (CF) came in at $4.0 million for Q1 2026 at Vireo Growth, down from $11.9 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $11.9 million in Q4 2025 to a low of $600000.0 in Q1 2025.
- The 5-year median for Depreciation & Amortization (CF) is $776991.0 (2022), against an average of $1.7 million.
- Across the five-year window, Depreciation & Amortization (CF) slipped 29.08% in 2024 and jumped 1774.66% in 2025, its largest moves.
- Vireo Growth's Depreciation & Amortization (CF) stood at $889195.0 in 2022, then declined by 26.84% to $650503.0 in 2023, then decreased by 2.29% to $635583.0 in 2024, then surged by 1774.66% to $11.9 million in 2025, then sank by 66.43% to $4.0 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $4.0 million (Q1 2026), $11.9 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 635,583.00 |
| Dec 31, 2024 | 635,583.00 |
| Sep 30, 2024 | 633,586.00 |
| Sep 30, 2024 | 633,586.00 |
| Jun 30, 2024 | 633,884.00 |
| Jun 30, 2024 | 633,884.00 |
| Mar 31, 2024 | 633,728.00 |
| Mar 31, 2024 | 633,728.00 |
| Dec 31, 2023 | 650,503.00 |
| Dec 31, 2023 | 650,503.00 |